 BioMarin Pharmaceutical Inc a drug maker focused on rare diseases said it has agreed to pay up to  million to acquire Prosensa Holding NV a Dutch biopharmaceutical company with no marketed products The deal is a bet that regulators will approve Prosensas lead product candidate for a rare form of muscular dystrophy despite the drugs
  